Cost Analysis of Aprotinin Reintroduction in French Cardiac Surgery Centres: A Real-World Data-Based Analysis
Authors:
- Pascal ColsonPCPascal Colson
- from the ARCOTHOVA GroupFGfrom the ARCOTHOVA Group
Open Access
- 3 March 2023
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 40 (4) , 1803-1817
Abstract
Introduction The European Medicines Agency restored aprotinin (APR) use for preventing blood loss in patients undergoing isolated coronary artery bypass graft (iCABG) in 2016 but requested the collection of patient and surgery data in a registry (NAPaR). The aim of this analysis was to evaluate the impact of APR reintroduction in France on the main hospital costs (operating room, transfusion and intensive unit stay) compared to the current use of tranexamic acid (TXA), which was the only antifibrinolytic available before APR reinstatement. Methods A multicenter before-after post-hoc analysis to compare APR and TXA was carried out in four French university hospitals. APR use followed the ARCOTHOVA (French Association of Cardiothoracic and Vascular Anesthetists) protocol, which had framed three main indications in 2018. Data from 236 APR patients were retrieved from the NAPaR (N = 874); 223 TXA patients were retrospectively retrieved from each center database and matched to APR patients upon indication classes. Budget impact was evaluated using both direct costs associated with antifibrinolytics and transfusion products (within the first 48 h) and other costs such as surgery duration and ICU stay. Results The 459 collected patients were distributed as: 17% on-label; 83% off-label. Mean cost per patient until ICU discharge tended to be lower in the APR group versus the TXA group, which resulted in an estimated gross saving of €3136 per patient. These savings concerned operating room and transfusion costs but were mainly driven by reduced ICU stays. When extrapolated to the whole French NAPaR population, the total savings of the therapeutic switch was estimated at around €3 million. Conclusion The budget impact projected that using APR according to ARCOTHOVA protocol resulted in decreased requirement for transfusion and complications related to surgery. Both were associated with substantial cost savings from the hospital’s perspective compared with exclusive use of TXA.Keywords
All Related Versions
Funding Information
- Nordic Pharma Group
This publication has 28 references indexed in Scilit:
- Increased perioperative mortality following aprotinin withdrawal: a real-world analysis of blood management strategies in adult cardiac surgeryIntensive Care Medicine, 2013
- The Papworth Bleeding Risk Score: a stratification scheme for identifying cardiac surgery patients at risk of excessive early postoperative bleedingEuropean Journal of Cardio-Thoracic Surgery, 2011
- Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysisCritical Care, 2010
- The Risk-Benefit Profile of Aprotinin Versus Tranexamic Acid in Cardiac SurgeryAnesthesia & Analgesia, 2010
- A Comparison of Aprotinin and Lysine Analogues in High-Risk Cardiac SurgeryNew England Journal of Medicine, 2008
- Aprotinin in Cardiac Surgery: A Review of Conventional and Novel Mechanisms of ActionAnesthesia & Analgesia, 2007
- Development and validation of Transfusion Risk Understanding Scoring Tool (TRUST) to stratify cardiac surgery patients according to their blood transfusion needsTransfusion, 2006
- Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting*Critical Care Medicine, 2006
- Medical and Economic Impact of Aprotinin Use in Adult Cardiac SurgeryTransfusion Alternatives in Transfusion Medicine, 2004
- Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trialsThe Annals of Thoracic Surgery, 2004